Artisan Partners Limited Partnership Has $37.93 Million Stake in Myriad Genetics, Inc. (NASDAQ:MYGN)

Artisan Partners Limited Partnership raised its position in Myriad Genetics, Inc. (NASDAQ:MYGN) by 13.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 2,766,729 shares of the company’s stock after purchasing an additional 336,770 shares during the quarter. Artisan Partners Limited Partnership’s holdings in Myriad Genetics were worth $37,932,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in MYGN. Vanguard Group Inc. raised its holdings in shares of Myriad Genetics by 2.7% in the 4th quarter. Vanguard Group Inc. now owns 10,591,043 shares of the company’s stock valued at $145,203,000 after purchasing an additional 279,379 shares during the period. State Street Corp raised its stake in Myriad Genetics by 8.3% in the third quarter. State Street Corp now owns 4,703,442 shares of the company’s stock valued at $128,827,000 after buying an additional 359,685 shares during the period. Disciplined Growth Investors Inc. MN lifted its position in shares of Myriad Genetics by 21.1% in the third quarter. Disciplined Growth Investors Inc. MN now owns 2,527,435 shares of the company’s stock valued at $69,226,000 after buying an additional 440,107 shares during the last quarter. Sei Investments Co. lifted its position in shares of Myriad Genetics by 7.4% in the fourth quarter. Sei Investments Co. now owns 2,526,761 shares of the company’s stock valued at $34,642,000 after buying an additional 174,770 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Myriad Genetics by 1.0% during the 3rd quarter. Geode Capital Management LLC now owns 2,154,035 shares of the company’s stock worth $59,010,000 after acquiring an additional 21,220 shares during the period. Institutional investors and hedge funds own 99.02% of the company’s stock.

Analyst Upgrades and Downgrades

MYGN has been the topic of several research reports. StockNews.com upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating in a report on Tuesday. UBS Group lowered their price target on shares of Myriad Genetics from $18.00 to $16.00 and set a “neutral” rating on the stock in a report on Tuesday, February 25th. Bank of America reduced their price objective on Myriad Genetics from $13.00 to $11.00 and set an “underperform” rating for the company in a report on Monday, March 3rd. Stephens reiterated an “equal weight” rating and set a $20.00 target price on shares of Myriad Genetics in a research note on Thursday, January 16th. Finally, Raymond James restated an “outperform” rating and issued a $19.00 price target (down from $27.00) on shares of Myriad Genetics in a research note on Tuesday, February 25th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $21.89.

Myriad Genetics Stock Down 3.7 %

Shares of NASDAQ MYGN opened at $8.88 on Friday. The stock has a market capitalization of $810.82 million, a P/E ratio of -6.83 and a beta of 1.79. The stock’s fifty day moving average is $11.76 and its 200 day moving average is $16.57. Myriad Genetics, Inc. has a 52 week low of $8.70 and a 52 week high of $29.30. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90.

Myriad Genetics (NASDAQ:MYGN) last released its earnings results on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.12). Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%. The firm had revenue of $210.60 million during the quarter, compared to the consensus estimate of $210.35 million. During the same period in the prior year, the business earned ($0.12) earnings per share. Sell-side analysts forecast that Myriad Genetics, Inc. will post -0.3 earnings per share for the current fiscal year.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.